| T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas SM Pollack, Q He, JH Yearley, R Emerson, M Vignali, Y Zhang, ... Cancer 123 (17), 3291-3304, 2017 | 257 | 2017 |
| Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ... Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022 | 229 | 2022 |
| Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer YD Seo, X Jiang, KM Sullivan, FG Jalikis, KS Smythe, A Abbasi, M Vignali, ... Clinical Cancer Research 25 (13), 3934-3945, 2019 | 199 | 2019 |
| NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma SM Pollack, AA Jungbluth, BL Hoch, EA Farrar, M Bleakley, DJ Schneider, ... Cancer 118 (18), 4564-4570, 2012 | 146 | 2012 |
| Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment KC Shibuya, VK Goel, W Xiong, JG Sham, SM Pollack, AM Leahy, ... PloS one 9 (5), e96565, 2014 | 142 | 2014 |
| Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial S Zhang, K Kohli, RG Black, L Yao, SM Spadinger, Q He, VG Pillarisetty, ... Cancer immunology research 7 (8), 1237-1243, 2019 | 134 | 2019 |
| Novel therapeutic approaches in chondrosarcoma G Polychronidou, V Karavasilis, SM Pollack, PH Huang, A Lee, RL Jones Future Oncology 13 (7), 637-648, 2017 | 125 | 2017 |
| Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial SM Pollack, MW Redman, KK Baker, MJ Wagner, BA Schroeder, ... JAMA oncology 6 (11), 1778-1782, 2020 | 113 | 2020 |
| Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone E Palmerini, RL Jones, E Marchesi, A Paioli, M Cesari, A Longhi, ... BMC cancer 16, 1-8, 2016 | 111 | 2016 |
| Emerging targeted and immune-based therapies in sarcoma SM Pollack, M Ingham, MB Spraker, GK Schwartz Journal of Clinical Oncology 36 (2), 125-135, 2018 | 90 | 2018 |
| First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1 N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do, P Hwu, JP Eder, ... Clinical Cancer Research 25 (19), 5808-5817, 2019 | 88 | 2019 |
| A contemporary large single-institution evaluation of resected retroperitoneal sarcoma PJ Bremjit, RL Jones, X Chai, G Kane, ET Rodler, ET Loggers, SM Pollack, ... Annals of surgical oncology 21, 2150-2158, 2014 | 86 | 2014 |
| NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine SM Pollack, Y Li, MJ Blaisdell, EA Farrar, J Chou, BL Hoch, ET Loggers, ... PloS one 7 (2), e32165, 2012 | 86 | 2012 |
| More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments D Katz, E Palmerini, SM Pollack American Society of Clinical Oncology Educational Book 38, 925-938, 2018 | 82 | 2018 |
| Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells SM Pollack, RL Jones, EA Farrar, IP Lai, SM Lee, J Cao, VG Pillarisetty, ... Journal for immunotherapy of cancer 2, 1-10, 2014 | 80 | 2014 |
| MRI radiomic features are independently associated with overall survival in soft tissue sarcoma MB Spraker, LS Wootton, DS Hippe, KC Ball, JC Peeken, MW Macomber, ... Advances in radiation oncology 4 (2), 413-421, 2019 | 73 | 2019 |
| Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial SP D'Angelo, DM Araujo, ARA Razak, M Agulnik, S Attia, JY Blay, ... The Lancet 403 (10435), 1460-1471, 2024 | 70 | 2024 |
| The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients SM Pollack Expert review of vaccines 17 (2), 107-114, 2018 | 64 | 2018 |
| First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma … SM Pollack, H Lu, S Gnjatic, N Somaiah, RB O’Malley, RL Jones, FJ Hsu, ... Journal of immunotherapy 40 (8), 302-306, 2017 | 64 | 2017 |
| NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022: Featured Updates to the NCCN Guidelines M von Mehren, JM Kane, RF Riedel, JK Sicklick, SM Pollack, M Agulnik, ... Journal of the National Comprehensive Cancer Network 20 (11), 1204-1214, 2022 | 63 | 2022 |
Robin JonesROYAL MARSDEN AND INSTITUE OF CANCER RESEARCHCorreu electrònic verificat a doctors.org.uk